Equillium Inc

Equillium, Inc. is a clinical-stage biotechnology company that develops therapeutics for severe autoimmune and inflammatory disorders, also known as immuno-inflammatory disorders, in the United States. Its pipeline includes EQ504, a novel AhR modulator in preclinical development for ulcerative colitis and lung inflammation diseases, and EQ302, an orally formulated bi-specific inhibitor of IL-15 and IL-21 for celiac disease. The company was formerly named Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium was incorporated in 2017 and is headquartered in La Jolla, California.